Salma Health raises $80M for its clinics to treat brain health
A clinic that wants to use AI to move mental health treatment beyond trial-and-error prescribing to more precise care based on patients’ health data has raised $80 million in Series A funding,...
View ArticleInvestors are pumping money into AI tools for health insurers
In the past month, payer AI startups including Anterior, Daffodil Health and Alaffia Health all raised tens of millions in fresh venture funding as insurers strive to match hospitals and health systems...
View ArticleNovartis to build another radioligand factory; Germany steps up probe into...
Novartis is building a new 46,000-square-foot factory in Denton, TX. Construction will start this year and is expected to be operational in 2028. The new facility is a part of its ...
View ArticleProtagonist to opt out of Takeda profit-sharing deal, will receive $400M in cash
Protagonist Therapeutics will soon receive a significant amount of cash. Protagonist will opt out of its profit-sharing deal with Takeda on a rare disease drug, the biotech announced Wednesday,...
View ArticleAtaiBeckley stock drops on Phase 2a data; Disc to refile rare disease drug
Plus, news about Boehringer Ingelheim, Sitryx Therapeutics, Argenx, Palvella Therapeutics, Vir Biotechnology, Larimar Therapeutics, Bristol Myers Squibb and SystImmune: 📉 AtaiBeckley releases Phase 2a...
View ArticleWhy did my doctor push Grail’s dubious cancer test?
Last year, my primary care physician tried to sell me on Grail’s cancer-detecting blood test. As I approached my 30th birthday, I wanted to start taking better care of my health. A friend recommended a...
View ArticleViatris plans to lay off up to 10% of staff, discloses Indian factory fire
Viatris said it's planning to cut up to 10% of its global workforce in an effort to save up to $700 million a year. In its fourth-quarter earnings report, the generic drugmaker on Thursday also ...
View ArticleSenate hearing raises FDA-related concerns for new rare disease drugs
Rare disease advocates and senators said they want to see more consistency in the FDA’s approval process during an Aging Committee hearing Thursday that examined how the agency’s regulatory processes...
View ArticleBoehringer wins accelerated approval for first-line use of lung cancer drug
The FDA greenlit an expanded label for Boehringer Ingelheim’s lung cancer drug Hernexeos, marking the first use of the Commissioner's National Priority Voucher for a new indication. Boehringer won an...
View ArticleFDA probes internal Prasad complaints with outside help
The FDA has been using an outside investigator in a probe of workplace complaints against CBER Director Vinay Prasad, a source familiar with the matter told Endpoints News. Among complaints made...
View ArticleDoug Ingram’s force of will meets its match as Sarepta CEO plans to depart
Doug Ingram’s decision to step down as Sarepta’s CEO by year's end was a shocker, considering his never-say-die reputation. But after a terrible year and a tanking share price, Sarepta's next leader...
View ArticleDOJ urges Supreme Court to undo revival of Hikma ‘skinny label’ case
The US solicitor general is calling on the Supreme Court to reverse a decision that he says would undermine a pathway commonly used to bring new generic drugs to market. The case centers on the ...
View ArticleDoug Ingram’s uneven legacy at Sarepta; Merck splits human health business,...
→ Merck said this week that it would divide its human health business into two groups — an oncology business unit and a specialty, pharma & infectious diseases business unit — suggesting that ...
View ArticleNovo Nordisk’s ‘strategic conundrum’: How being anchored to the past could...
It’s possible to imagine a world in which Novo Nordisk remained a medium-to-large European pharma company, a little like Merck KGaA or Boehringer Ingelheim, ticking over for hundreds of years, quietly...
View ArticleNovartis closes Avidity deal as rare heart disease spinout launches
Atrium Therapeutics launched Friday morning as Novartis closed the $12 billion deal to buy Avidity Biosciences and its RNA muscle therapies. The spinout will take on Avidity’s early-stage programs for...
View ArticlePadcev-Keytruda combo delivers more positive data in bladder cancer
Researchers have rolled out another win for the Padcev-Keytruda combination, this time as a first treatment for a form of bladder cancer. It's the second recent win for the combo after last year's...
View ArticleGinkgo divests biosecurity arm; J&J's early prostate cancer data
⚠️ Ginkgo Bioworks' biosecurity deal: The company is selling its biosecurity unit to a "consortium of investors," which will operate it as a standalone business. In exchange, Ginkgo will get ...
View ArticleWuXi XDC makes an ADC linker deal with Earendil for up to $885M
WuXi Biologics' antibody-drug conjugate spinout WuXi XDC said on Friday that it will be working with Earendil Labs to develop new ADCs. AI-driven biologics developer Earendil will have access to WuXi ...
View ArticleGenerate:Biomedicines raises $400M IPO, CEO talks about AI's future in drug...
A leader of the next wave of AI-driven biotechs completed one of the industry's largest IPOs in years, although the milestone was tarnished by a rough first few hours of trading for the new stock ...
View ArticleCHMP recommends Moderna's flu-Covid shot and Novartis pill for hives
The European Medicines Agency’s human medicines committee recommended approving six new medicines, including Moderna's flu-Covid-19 combo vaccine and Novartis' pill for hives. CHMP gives its...
View ArticleMerck cuts more than 150 jobs at new Gardasil vaccine plant in North Carolina
Merck is shedding more than 150 jobs in North Carolina, almost all of which are tied to a vaccine manufacturing plant that was unveiled less than a year ago. The headcount reductions were disclosed in ...
View ArticleUS International Trade Commission to take a closer look at Chinese biotech
The US International Trade Commission is opening an investigation into China's support for biotech as well as the country's pricing practices, looking at whether the government there "manipulated...
View ArticleNovartis, Takeda to enter next Medicare drug price negotiations
At least two big pharma companies have said they will participate in the upcoming third round of Medicare negotiations under the Inflation Reduction Act, as court challenges against the program...
View ArticleAscendis wins FDA approval for achondroplasia drug, waits on EU action
The FDA on Friday approved Ascendis Pharma’s once-weekly treatment for achondroplasia, a form of dwarfism, setting up what could become a three-way competition among drugmakers. The drug, known as...
View Article